Erman Akkus/X
Jun 8, 2025, 08:52
Erman Akkus: Early Bevacizumab Modifications are Linked to Worse OS in Advanced HCC
Erman Akkus, Medical Oncology Fellow at Ankara University, shared a post on X about a paper by F. Rossari et al. published in ESMO Gastrointestinal Oncology:
“Early bevacizumab dose and time modifications – worse OS in advanced HCC treated with atezo-beva in ESMO Gastrointestinal Oncology.”
Title: Early bevacizumab dose and time modifications may affect efficacy of atezolizumab plus bevacizumab for advanced hepatocellular carcinoma treatment
Authors: F. Rossari, D. Lavacchi, E. Alimenti, C. Soldà, F. Salani, L. Esposito, S. Foti, S. Camera, M. Persano, F. Lo Prinzi, F. Vitiello, E. Pellegrini, M. Bruccoleri, M.D. Rizzato, M. Caccese, I.G. Rapposelli, A. Guidolin, A. De Rosa, L. Antonuzzo, G. Masi, M.A. Iavarone, S. Lonardi, M. Rimini, A. Casadei-Gardini
You can read the Full Article in ESMO Gastrointestinal Oncology.
More posts featuring Erman Akkus.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jun 8, 2025, 08:43